{"organizations": [], "uuid": "761ad35ebc306296e33f09d0dd2fd091f67462e4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "in.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/INhealth\r", "section_title": "Reuters: Health", "url": "https://in.reuters.com/article/us-fda-approval/fda-approves-first-non-opioid-drug-to-treat-opioid-withdrawal-symptoms-idINKCN1IH30J", "country": "US", "domain_rank": 408, "title": "FDA approves first non-opioid drug to treat opioid withdrawal symptoms", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-17T00:14:00.000+03:00", "replies_count": 0, "uuid": "761ad35ebc306296e33f09d0dd2fd091f67462e4"}, "author": "", "url": "https://in.reuters.com/article/us-fda-approval/fda-approves-first-non-opioid-drug-to-treat-opioid-withdrawal-symptoms-idINKCN1IH30J", "ord_in_thread": 0, "title": "FDA approves first non-opioid drug to treat opioid withdrawal symptoms", "locations": [], "entities": {"persons": [{"name": "lucemyra", "sentiment": "none"}], "locations": [{"name": "lucemyra", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "worldmeds llc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "u.s. centers for disease control and prevention", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - The U.S. Food and Drug Administration on Wednesday approved here the first non-opioid drug that will help reduce symptoms of opioid withdrawal in adults.\nThe drug, Lucemyra, is an oral treatment from US WorldMeds LLC, and is only approved for treatment of up to 14 days.\nOpioid withdrawal includes symptoms — such as anxiety, agitation, sweating, vomiting, diarrhea and drug craving — that occur after stopping or reducing the use of opioids.\nThe application was granted priority review and fast track designations, and an independent FDA advisory committee supported the approval of Lucemyra at a meeting held in March.\nThe approval comes at a time when the United States is facing an opioid epidemic.\nOpioids were involved in more than 42,000 overdose deaths in 2016, the last year for which data was available, according to the U.S. Centers for Disease Control and Prevention.\nLucemyra is not a treatment for opioid use disorder (OUD), but can be used to manage OUD as part of a long-term plan, the drugs regulator said.\nReporting by Mrinalini Krothapalli; Editing by Sriraj Kalluvila\nOur Standards: The Thomson Reuters Trust Principles. 0 : 0 narrow-browser-and-phone medium-browser-and-portrait-tablet landscape-tablet medium-wide-browser wide-browser-and-larger medium-browser-and-landscape-tablet medium-wide-browser-and-larger above-phone portrait-tablet-and-above above-portrait-tablet landscape-tablet-and-above landscape-tablet-and-medium-wide-browser portrait-tablet-and-below landscape-tablet-and-below Apps Newsletters Reuters Plus Advertising Guidelines Cookies Terms of Use Privacy\nAll Quote: s delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.\n© 2018 Reuters. All Rights Reserved.", "external_links": ["https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607884.htm"], "published": "2018-05-17T00:14:00.000+03:00", "crawled": "2018-05-17T01:04:30.023+03:00", "highlightTitle": ""}